153 related articles for article (PubMed ID: 23276977)
21. Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer.
Mangili G; Picchio M; Sironi S; Viganò R; Rabaiotti E; Bornaghi D; Bettinardi V; Crivellaro C; Messa C; Fazio F
Eur J Nucl Med Mol Imaging; 2007 May; 34(5):658-666. PubMed ID: 17180659
[TBL] [Abstract][Full Text] [Related]
22. Impact of Fluorodeoxyglucose PET/Computed Tomography on the Management of Patients with Colorectal Cancer.
Laurens ST; Oyen WJ
PET Clin; 2015 Jul; 10(3):345-60. PubMed ID: 26099671
[TBL] [Abstract][Full Text] [Related]
23. Prognostic importance of peritoneal lesion-to-primary tumour standardized uptake value ratio in advanced serous epithelial ovarian cancer.
Chung HH; Kim JW; Park NH; Song YS; Cheon GJ
Eur Radiol; 2018 May; 28(5):2107-2114. PubMed ID: 29260365
[TBL] [Abstract][Full Text] [Related]
24. Value of CT, FDG PET-CT and serum tumor markers in staging recurrent colorectal cancer.
Caglar M; Yener C; Karabulut E
Int J Comput Assist Radiol Surg; 2015 Jul; 10(7):993-1002. PubMed ID: 25213271
[TBL] [Abstract][Full Text] [Related]
25. Clinical impact of fluorodeoxyglucose-positron emission tomography scan/computed tomography in comparison with computed tomography on the detection of colorectal cancer recurrence.
Deleau C; Buecher B; Rousseau C; Kraeber-Bodéré F; Flamant M; des Varannes SB; Frampas E; Galmiche JP; Matysiak-Budnik T
Eur J Gastroenterol Hepatol; 2011 Mar; 23(3):275-81. PubMed ID: 21304319
[TBL] [Abstract][Full Text] [Related]
26. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
27. Fludeoxyglucose F 18 PET-Computed Tomography: Management Changes Effecting Patient Outcomes in Gynecologic Malignancies.
Brunetti JC
PET Clin; 2015 Jul; 10(3):395-409. PubMed ID: 26099674
[TBL] [Abstract][Full Text] [Related]
28. Role of FDG PET/CT in staging of recurrent ovarian cancer.
Son H; Khan SM; Rahaman J; Cameron KL; Prasad-Hayes M; Chuang L; Machac J; Heiba S; Kostakoglu L
Radiographics; 2011; 31(2):569-83. PubMed ID: 21415197
[TBL] [Abstract][Full Text] [Related]
29. Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent ovarian cancer: comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT.
Kitajima K; Murakami K; Yamasaki E; Domeki Y; Kaji Y; Fukasawa I; Inaba N; Suganuma N; Sugimura K
Eur J Nucl Med Mol Imaging; 2008 Aug; 35(8):1439-48. PubMed ID: 18418592
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of ¹⁸F-FDG PET/MRI, ¹⁸F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer.
Sawicki LM; Grueneisen J; Schaarschmidt BM; Buchbender C; Nagarajah J; Umutlu L; Antoch G; Kinner S
Eur J Radiol; 2016 Feb; 85(2):459-65. PubMed ID: 26781152
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of preoperative intratumoral FDG uptake heterogeneity in patients with epithelial ovarian cancer.
Lee M; Lee H; Cheon GJ; Kim HS; Chung HH; Kim JW; Park NH; Song YS
Eur Radiol; 2017 Jan; 27(1):16-23. PubMed ID: 27121932
[TBL] [Abstract][Full Text] [Related]
32. Impact of FDG-PET and -PET/CT imaging in the clinical decision-making of ovarian carcinoma: an evidence-based approach.
Kumar Dhingra V; Kand P; Basu S
Womens Health (Lond); 2012 Mar; 8(2):191-203. PubMed ID: 22375721
[TBL] [Abstract][Full Text] [Related]
33. Detection of nodal metastases by 18F-FDG PET/CT in apparent early stage ovarian cancer: a prospective study.
Signorelli M; Guerra L; Pirovano C; Crivellaro C; Fruscio R; Buda A; Cuzzucrea M; Elisei F; Ceppi L; Messa C
Gynecol Oncol; 2013 Nov; 131(2):395-9. PubMed ID: 23988414
[TBL] [Abstract][Full Text] [Related]
34. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
Thrall MM; DeLoia JA; Gallion H; Avril N
Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284
[TBL] [Abstract][Full Text] [Related]
35. Role of FDG PET-CT in asymptomatic epithelial ovarian cancer with rising serum CA-125: a pilot study.
Ghosh J; Thulkar S; Kumar R; Malhotra A; Kumar A; Kumar L
Natl Med J India; 2013; 26(6):327-31. PubMed ID: 25073988
[TBL] [Abstract][Full Text] [Related]
36. Role of PET/CT in ovarian cancer.
Prakash P; Cronin CG; Blake MA
AJR Am J Roentgenol; 2010 Jun; 194(6):W464-70. PubMed ID: 20489063
[TBL] [Abstract][Full Text] [Related]
37. Positron emission tomography/computed tomography predictors of overall survival in stage IIIC/IV ovarian cancer.
Risum S; Loft A; Engelholm SA; Høgdall E; Berthelsen AK; Nedergaard L; Lundvall L; Høgdall C
Int J Gynecol Cancer; 2012 Sep; 22(7):1163-9. PubMed ID: 22810969
[TBL] [Abstract][Full Text] [Related]
38. The value of [18F]fluorodeoxyglucose-PET/CT in oesophageal cancer.
Rankin S
Cancer Imaging; 2011 Oct; 11 Spec No A(1A):S156-60. PubMed ID: 22186083
[TBL] [Abstract][Full Text] [Related]
39. FDG-PET/CT in advanced ovarian cancer staging: value and pitfalls in detecting lesions in different abdominal and pelvic quadrants compared with laparoscopy.
De Iaco P; Musto A; Orazi L; Zamagni C; Rosati M; Allegri V; Cacciari N; Al-Nahhas A; Rubello D; Venturoli S; Fanti S
Eur J Radiol; 2011 Nov; 80(2):e98-103. PubMed ID: 20688446
[TBL] [Abstract][Full Text] [Related]
40. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125.
Rubini G; Altini C; Notaristefano A; Merenda N; Rubini D; Ianora AA; Asabella AN
Rev Esp Med Nucl Imagen Mol; 2014; 33(1):22-7. PubMed ID: 23948509
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]